Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

Fineline Cube May 20, 2026
Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026
Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026
Company Deals

Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting “Undruggable” Proteins

Fineline Cube May 19, 2026
Company Deals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Bayer’s Asundexian Receives FDA Priority Review for Secondary Stroke Prevention Following Positive Phase III OCEANIC-STROKE Trial

Fineline Cube May 20, 2026
Company Drug

United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization

Fineline Cube May 20, 2026
Company Drug

Simcere’s Edaravone, Borneol Sublingual Tablets Reach Phase III Efficacy Endpoint

Fineline Cube Dec 2, 2022

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) announced that a Phase III clinical study for...

Digital R&D

AI Model for Early Alzheimer’s Detection Using Retinal Photographs Published

Fineline Cube Dec 2, 2022

A joint Singapore-UK-Hong Kong research team has published details of an AI-based deep learning model...

Company Deals

XJTLU and University of Liverpool Launch Joint Centre for Pharmacology and Therapeutics

Fineline Cube Dec 2, 2022

The Suzhou-based Xi’an Jiaotong-Liverpool University (XJTLU) and the UK’s University of Liverpool earlier this month...

Company Deals

Yifan Pharmaceutical Licenses F-627 to Acrotech for US Distribution

Fineline Cube Dec 2, 2022

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced the establishment of a licensing agreement with...

Company Deals Digital

Nans Tech Secures Series A Funding for Brain Dysfunction Digital Therapies

Fineline Cube Dec 1, 2022

Nans Tech, a brain dysfunction digital therapy developer based in Hangzhou, reportedly raised “tens of...

Company Deals

Aclaris Therapeutics Licenses JAK Inhibitor ATI-1777 to Pediatrix for Greater China

Fineline Cube Dec 1, 2022

US-based Aclaris Therapeutics Inc. (NASDAQ: ACRS) and Shanghai firm Pediatrix Therapeutics Inc. entered into a...

Policy / Regulatory

China’s NMPA Issues New GSP Appendix for Drug Retailing Quality Management

Fineline Cube Dec 1, 2022

China’s National Medical Products Administration (NMPA) has released “Good Supply Practice (GSP) Appendix 6: Quality...

Company Drug

ImmuneOnco Initiates Phase II Clinical Study for CD47 Antibody IMM01

Fineline Cube Dec 1, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced the initiation of a Phase II clinical study...

Policy / Regulatory

China’s NMPA Seeks Feedback on Drug Quality Management Provisions

Fineline Cube Dec 1, 2022

China’s National Medical Products Administration (NMPA) has released a draft proposal titled “Provisions on the...

Company Deals

Luye Pharma’s Shandong Boan Bio Files for Hong Kong IPO

Fineline Cube Dec 1, 2022

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd, has filed...

Company Deals

Luca Healthcare Partners with Cambridge Cognition to Launch Cognitive Tools in China

Fineline Cube Dec 1, 2022

China-based digital health solutions provider Luca Healthcare has announced a strategic partnership and license agreement...

Company Drug

Luye Pharma’s Biosimilar to Amgen’s Xgeva Launched in China

Fineline Cube Dec 1, 2022

China-based Luye Pharma Group (HKG: 2186) has announced the first prescription of its biosimilar version...

Company Medical Device

Assure Tech Wins Japanese PDMA Approval for Pen-Type COVID-19 Antigen Test

Fineline Cube Dec 1, 2022

China-based Assure Tech (Hangzhou) Co., Ltd (SHA: 688075) has announced receiving marketing approval from Japan’s...

Company Drug

Double-Crane Pharma Gains NMPA Approval for COVID-19 Drug CX2101A Clinical Trials

Fineline Cube Dec 1, 2022

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving clinical trial approval from...

Company Medical Device

Lepu Medical Wins NMPA Approval for Disposable Pressure Microcatheter

Fineline Cube Dec 1, 2022

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Policy / Regulatory

China’s NMPA Shifts to Electronic Drug Filings from January 2023

Fineline Cube Dec 1, 2022

China’s National Medical Products Administration (NMPA) has released a notification indicating the initiation of electronic...

Company Medical Device

Hainan Hospital Launches IBI’s Smartbone ORTHO for Bone Repair

Fineline Cube Dec 1, 2022

The clinical application of Smartbone ORTHO, a polyester collagen bone repair material introduced by Hainan...

Company Drug

CSL Vifor and Fresenius Kabi Win China Approval for Ferinject

Fineline Cube Dec 1, 2022

Swiss firm CSL Vifor and Germany’s Fresenius Kabi have announced the first regulatory approval in...

Company Deals

China’s Pharma Firms Collaborate on Generic Version of Sun Pharma’s Carbamazepine

Fineline Cube Dec 1, 2022

Several China-based pharmaceutical companies, including Shanghai Zhongxi Sunve Pharmaceutical Co. Ltd, Shanghai Anbison Lab Co.,...

Company Drug

Youcare’s YKYYO17 Aerosol Inhalation Agent Approved for COVID-19 Clinical Study

Fineline Cube Dec 1, 2022

China-based Youcare Pharmaceutical Group’s YKYYO17 aerosol inhalation agent, a broad-spectrum coronavirus membrane fusion inhibitor polypeptide...

Posts pagination

1 … 595 596 597 … 668

Recent updates

  • Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo
  • Bayer’s Asundexian Receives FDA Priority Review for Secondary Stroke Prevention Following Positive Phase III OCEANIC-STROKE Trial
  • UCB’s BIMZELX Demonstrates Superior Joint Outcomes vs SKYRIZI in Phase III BE BOLD Trial for Psoriatic Arthritis
  • United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization
  • ImmuneOnco Doses First Patient in Phase II Trial of IMM0306 for Systemic Lupus Erythematosus
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

Company Drug

Bayer’s Asundexian Receives FDA Priority Review for Secondary Stroke Prevention Following Positive Phase III OCEANIC-STROKE Trial

Others

UCB’s BIMZELX Demonstrates Superior Joint Outcomes vs SKYRIZI in Phase III BE BOLD Trial for Psoriatic Arthritis

Company Drug

United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.